Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
Provider: Directors Deals Ltd.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

West Pharmaceutical Services Inc Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance

Thursday, 2 May 2013 07:00am EDT 

West Pharmaceutical Services Inc announced that for fiscal 2013, it expects consolidated net sales to be in the range of $1,360 to $1,400 million (prior guidance was $1,360 to $1,400), adjusted diluted earnings per share (EPS) to be in the range of $3.05 to $3.20 ( prior guidance was $2.97 to $3.17) and diluted EPS to be in the range of $3.08 to $3.23 ( prior guidance was $3.00 to $3.20 ). The Company's estimated guidance for 2013 includes $6 million in expected sales and development income, and between $0.06 and $0.08 of adjusted diluted EPS, that are associated with customers' research and pre-commercial work with Daikyo Crystal Zenith and other proprietary administration devices, the nature of which increases the risk that actual results may be lower than estimates. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.375 billion and EPS of $3.13 for fiscal 2013. 

Company Quote

-0.04 -0.07%
26 Dec 2014